Personalized risk assessment for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial uses a prediction model to better estimate the risk of endometrial cancer coming back. It aims to help doctors and patients make more personalized treatment decisions after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early stage (FIGO stage I or II) endometrial cancer
- Any grade of your cancer is allowed
- You are able to have surgery as your main treatment (chemotherapy or hormone therapy before surgery is okay)
- You are not a native speaker of Dutch or English but can understand one of these languages
- You do not have a rare type of endometrial cancer like endometrial stromal sarcoma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
This study looks at combining genetic testing with surgical exams to better understand endometrial cancer. It may help doctors see which treatments could work best for you.
This trial looks at better ways to predict how aggressive your endometrial cancer is before surgery, so doctors can decide if they need to check your lymph nodes. It may help tailor your treatment to avoid unnecessary procedures.
This study looks at whether a blood test called Signatera can help find small amounts of cancer DNA after surgery for early-stage endometrial cancer. The goal is to see if this test can help guide treatment decisions and improve outcomes.
This study uses a risk model to detect endometrial cancer in people with unexplained abnormal uterine bleeding. It aims to find better ways to identify cancer early without relying only on invasive biopsies.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.